March 13, 2019

BSE Limited
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Re: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subject: U.S. FDA classifies the inspection of the Company's Mandideep (Unit 1) facility as OAI.

We wish to inform you that the Company has received a letter from the U.S. FDA classifying the inspection conducted at the Company's Mandideep (Unit 1) facility in December 2018 as 'Official Action Indicated' (OAI). The U.S. FDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.

There are no new DMF and ANDA applications pending review or approval from the Mandideep (Unit 1) facility and the Company does not believe that this classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The Company is in the process of sending further updates of its corrective actions to the U.S. FDA and remains hopeful of a positive outcome.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,

For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY